Skip to main content

Table 3 General characteristics of patients

From: Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

Characteristics   n= 34
Sex Male, n (%) 13 (38%)
Female, n (%) 21 (62%)
Age at exposure (yr) Mean ± SD 27 ± 9
Age at liver biopsy before treatment (yr) Mean ± SD 56 ± 10
Age at liver biopsy after treatment (yr) Mean ± SD 58 ± 10
Route of transmission Blood transfusion, n (%) 29 (85%)
Nosocomial, n (%) 5 (15%)
Duration of HCV exposure (yr) Mean ± SD 32 ± 10
HCV genotype Genotype 1, n (%) 24 (70%)&
Genotype 2, n (%) 4 (12%)&
Genotype 3, n (%) 2 (6%)
ND, n (%) 5 (15%)
Change in HCV viral load after treatment Increase 1 log, n (%) 1 (4%)
Unchanged*, n (%) 27 (96%)
Body mass index (Kg/m2) Mean (±SD) 28 ± 7**
  1. &A patient presented co-infection with two genotypes of VHC. *Unchanged: modification less than 1 log in viral load; * *Overweight according to OMS; ND: not determined. HCV: Hepatitis C virus.